REVUFORJ Gets FDA Patent Timer: Generic Delays on Deck
Published Date: 2/26/2026
Notice
Summary
The FDA has set the official review period for the drug REVUFORJ, which helps the company extend its patent and protect their invention longer. This affects the drug maker and anyone tracking patent timelines, with deadlines to challenge or comment by April 27 and August 25, 2026. It’s a key step in making sure the patent extension process is fair and on schedule, potentially impacting when generic versions can enter the market.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
FDA Sets REVUFORJ Review Length
The FDA determined REVUFORJ had a regulatory review period of 1,969 days total: 1,674 days in the testing phase and 295 days in the approval phase. Those totals are based on an investigational exemption effective June 28, 2019, an NDA submission on January 26, 2024, and approval on November 15, 2024.
Applicant Requests 525-Day Patent Extension
The patent applicant (Vitae Pharmaceuticals, LLC) has applied to the USPTO seeking 525 days of patent term extension for U.S. Patent No. 10,683,302 covering REVUFORJ. FDA's determination of the regulatory review period establishes the maximum potential length of any extension the USPTO may consider.
Determination May Affect Generic Entry Timing
FDA’s determination establishes the maximum potential patent extension period that the USPTO may use when calculating any patent term restoration, and the USPTO will apply statutory limitations in its final calculation. That process can affect when generic versions of REVUFORJ are legally able to enter the market.
Deadlines to Challenge or Petition
Anyone who believes the published dates are incorrect may ask for a redetermination by April 27, 2026, and any interested person may petition FDA about the applicant's diligence during the regulatory review period by August 25, 2026. Petitions must meet the requirements in 21 CFR 60.30 and be timely and properly filed.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-03843 — Agency Information Collection Activities: Proposed Request
The Social Security Administration wants your thoughts on some forms they use to pick people who manage benefits for others. They’re updating these forms and asking for feedback by April 27, 2026, to make sure the process is clear and easy. This affects individuals and organizations applying to be payees, with no new costs but a chance to reduce paperwork hassle.
Next: 2026-03848 — Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
The FDA has set the official review period for ORLYNVAH, a human drug, which helps decide how long its patent can be extended. This affects the drug’s maker by potentially giving them more time to protect their invention and earn money. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until April 27 or August 25, 2026, to speak up.